Arsenic trioxide (As 2 O 3 ) is a potent antitumor agent used to treat acute promyelocytic leukemia (APL) and, more recently, solid tumors. However, the dose of As 2 O 3 required to suppress human xenographs in mice is markedly higher than that used to treat APL in humans. Paradoxically, low doses of As 2 O 3 stimulate angiogenesis, which might be expected to promote tumor growth. Clearly, appropriate dosages of As 2 O 3 are required to treat human patients to avoid toxicity and undesirable side effects. In the present study, we investigated As 2 O 3 with respect to its toxicity and effects on tumor growth, angiogenesis and cell apoptosis using H22 hepatocellular carcinoma (HCC) cells in a mouse model of HCC. As 2 O 3 inhibited tumor growth and angiogenesis, and enhanced tumor cell apoptosis at doses greater than 1 mg/kg, but mice lost weight and failed to thrive at doses of 4 mg/kg and greater. In contrast, low doses (<1 mg/kg) of As 2 O 3 promoted tumor growth, upregulated the expression of vascular endothelial growth factor and tumor angiogenesis, and had no effect on tumor cell apoptosis. In vitro studies demonstrated that As 2 O 3 inhibited the proliferation of H22 tumor cells and bovine aortic endothelial cells, and induced their apoptosis in a dose-and time-dependent fashion, suggesting that the mechanism of As 2 O 3 -mediated inhibition of tumor growth is due to direct effects of the drug on both tumor cells and endothelia. In summary, different doses of As 2 O 3 have opposing effects on tumor growth and angiogenesis. The results demonstrate that As 2 O 3 has a narrow window of therapeutic opportunity with respect to dosage, and that low doses of the drug as used in metronomic therapy should be used with extreme caution. (Cancer Sci 2006; 97: 675-681) A rsenic trioxide has been used as an anticancer agent in traditional Chinese medicine for several thousand years. It was originally shown to induce complete clinical remission in patients with APL at Harbin Medical University in China in the 1970s.(1) It has subsequently been widely employed to treat APL, including the treatment of patients that are resistant to conventional chemotherapies. The therapeutic potential and antitumor activity of As 2 O 3 extends to non-APL leukemia, and to a variety of solid tumors and tumor cell lines including neuroblastoma,head and neck, (4) gastric,transitional,renal,esophageal,prostate,colorectal (10) and hepatocellular (11) cancers or cell lines. However, the activity of As 2 O 3 against solid tumors has not been as effective as against APL. As 2 O 3 induces the apoptosis of various cancer cell lines (3)(4)(5)(6)(7) and inhibits the growth of tumors, (8,9,12) but the dosages of As 2 O 3 required to exert these effects (9,(12)(13)(14) are much higher than those required to inhibit hematologic malignancies. (15,16) Such high doses are not clinically achievable without the risk of severe side effects due to toxicity. A review of recently published reports in which As 2 O 3 was used to treat solid tumors in mice reveals that...